Chinese Japanese Germany Korea


Indications and Usage Mechanisms of Action Pharmacokinetics Adverse Effects
Tenofovir structure
Chemical Name:
Viread;9-Pmpa;GS-1278;GS 1275;Tenofovi;(R)-PMPA;TENOFOVIR;Tenefovir;Apropovir;Aids021800
Molecular Formula:
Formula Weight:
MOL File:

Tenofovir Properties

Melting point:
D +21° (c = 1 in 0.1M HCl)
Boiling point:
616.1±65.0 °C(Predicted)
1.79±0.1 g/cm3(Predicted)
storage temp. 
Store at -20°C
white to beige
optical activity
[α]/D -20 to -26°, c = 0.5 in 1 M HCl
Water Solubility 
13.4 mg/mL (25 ºC)
CAS DataBase Reference
147127-20-6(CAS DataBase Reference)
  • Risk and Safety Statements
RTECS  SZ6563600
HS Code  29339900

Tenofovir price More Price(6)

Manufacturer Product number Product description CAS number Packaging Price Updated Buy
TCI Chemical T3006 Tenofovir Hydrate >98.0%(HPLC)(T) 147127-20-6 1g $46 2020-06-24 Buy
TCI Chemical T3006 Tenofovir Hydrate >98.0%(HPLC)(T) 147127-20-6 5g $157 2020-06-24 Buy
Cayman Chemical 13874 Tenofovir ≥98% 147127-20-6 5mg $65 2020-06-24 Buy
Cayman Chemical 13874 Tenofovir ≥98% 147127-20-6 10mg $117 2020-06-24 Buy
Cayman Chemical 13874 Tenofovir ≥98% 147127-20-6 50mg $520 2020-06-24 Buy

Tenofovir Chemical Properties,Uses,Production

Indications and Usage

Tenofovir disoproxil (Viread) is the first nucleotide analogue approved by the American FDA to treat HIV-1 infections. Tenofovir disoproxil is a drug used in the AIDS cocktail treatment method, and research shows that it has the ability to increase monkeys’ immunity to immunodeficiency viruses (similar to the human AIDS virus). Tenofovir disoproxil is used in combination with other reverse transcriptase inhibitors to treat HIV-1 infections and hepatitis B.

Mechanisms of Action

Tenofovir disoproxil is an acyclic nucleoside antivirus drug and has an inhibiting effect on HBV multi-enzyme complexes and HIV reverse transcriptase. Its active content tenofovir phosphonate directly competitively binds to natural deoxyribose substrate to inhibit the virus multi-enzyme complex and inserts itself into the DNA to end the nucleotide chain. Tenofovir disoproxil is barely absorbed by the gastrointestinal duct, so it undergoes esterification and ionization to become tenofovir ester fumarate. Tenofovir is soluble in water and can be quickly absorbed and decomposed into the active substance tenofovir, which then transforms into the active metabolite tenofovir phosphonate. As this drug is not metabolized by the CYP450 enzyme system, it has a very low chance of drug interactions caused by this enzyme.


Tenofovir disoproxil reaches peak blood concentration 1-2 hours after intake. Tenofovir disoproxil’s bioavailability increases by about 40% when taken with food. The intracellular half-life of tenofovir phosphonate is about 10 hours, so doses can be taken once daily. This drug is mainly filtered through renal glomeruli and excreted through the renal tubule transport system, with 70-80% excreted in its original form through urine.

Adverse Effects

Chemical Properties

White Crystalline Solid


Tenofovir is a drug used for the treatment of chronic heptatitis B as well as prevention and treatment of HIV/AIDS. It is a kind of nucleotide analog, acting as the reverse-transcriptase inhibitor (NtRTI). It inhibits the activity of HIV reverse transcriptase through competing with the natural substrate deoxyadenosine 5’-triphosphate, causing the termination of DNA chain. 


ChEBI: A member of the class of phosphonic acids that is methylphosphonic acid in which one of the methyl hydrogens is replaced by a [(2R)-1-(6-amino-9H-purin-9-yl)propan-2-yl]oxy group. An inhibitor of HIV-1 reverse transcriptase, the bis(isopropyloxycarbonyloxy ethyl) ester (disoproxil ester) prodrug is used as the fumaric acid salt in combination therapy for the treatment of HIV infection.


Tenofovir disoproxil fumarate (Viread) is a prodrug of tenofovir, a phosphorylated adenosine nucleoside analogue, and is the only available agent of its class. It is converted by cellular enzymes to tenofovir diphosphate, which competes with deoxyadenosine triphosphate (dATP) for access to reverse transcriptase and causes chain termination following its incorporation. Tenofovir was approved as part of a combination therapy for HIV in adults who failed treatment with other regimens; it appears to be effective against HIV strains that are resistant to NRTIs.

Acquired resistance

HIV variants with the K65R mutation and the K70E mutation in the reverse transcriptase demonstrate reduced susceptibility to tenofovir.

Pharmaceutical Applications

A nucleotide analog structurally similar to adefovir.
EC50 values for HBV, assessed in the HepG2 2.2.15 cell line, ranged from 0.14 to 1.5 μm; the cytotoxic concentration exceeded 100 μm. A decline in HBV DNA levels below 105 copies/mL at 48 weeks of therapy in 100% of patients receiving tenofovir compared with 44% on adefovir therapy has been reported. There are also case reports of patients with primary resistance to adefovir responding to tenofovir.
It is generally well tolerated in patients with chronic HBV; the most common side effects include nausea and gastrointestinal upset, headache, dizziness, fatigue and rash.

Pharmaceutical Applications

An acyclic nucleoside phosphonate, formulated as the disoproxil fumarate salt for oral administration.

Biological Activity

Selectively inhibits HIV reverse transcriptase (RNA-dependent DNA polymerase). Prevents cytotoxicity in SIV-infected C-8166 cells in vitro (IC 50 = 1.5 μ M). Antiviral agent.


Oral absorption: c. 25%
Cmax 300 mg once daily: 0.3 mg/L
Plasma half-life: 17 h
Volume of distribution: 1.3 ± 0.6 L/kg at 3.0 mg/kg intravenous dose
Plasma protein binding: <0.7% (in vitro)
Absorption and distribution
Oral bioavailability is poor, but is enhanced by administration as the disoproxil prodrug. It may be taken with or without food. CSF penetration is likely to be minimal due to the anionic charge of the molecule at physiological pH. It accumulates in semen at higher concentrations than in plasma. It is not known if it is distributed into breast milk.
Metabolism and excretion
Tenofovir is not metabolized and is principally eliminated by the kidneys by a combination of glomerular filtration and active tubular secretion. In patients with renal dysfunction the dose should be adjusted accordingly.
Compounds such as cidofovir, aciclovir (acyclovir), valaciclovir, ganciclovir, valganciclovir and probenecid may compete for renal excretion. Tenofovir levels are increased when prescribed with some HIV protease inhibitors. The co-administration of tenofovir with didanosine leads to didanosine accumulation which is thought to occur through inhibition of purine nucleoside phosphorylase. This has been associated with impaired immune recovery and several cases of lactic acidosis and pancreatitis. If tenofovir is combined with didanosine the dose of didanosine should be reduced to 200 mg (<60 kg) or 250 mg (≥60 kg) per day and the patient monitored for symptoms of didanosine toxicity.

Clinical Use

Chronic hepatitis B infection

Clinical Use

Treatment of HIV infection in adults and children (in combination with other antiretroviral drugs)

Side effects

In clinical trials of antiretroviral treatment-naive participants, the most commonly reported adverse events were mild to moderate gastrointestinal upset (nausea 8%, diarrhea 11%), headache (14%) and depression (11%). Tenofovir has the potential to result in nephrotoxicity, particularly through proximal tubular damage, but the risk of clinically significant renal dysfunction appears relatively low and seems to occur mainly in subjects with other identifiable risks for renal impairment. Minor elevations in serum creatinine and reductions in creatinine clearance occur, but rarely require drug discontinuation.
A few (<0.1%) cases of osteomalacia and decreased bone density have been reported.

Side effects

Tenofovir is taken once daily and is generally well tolerated, perhaps because it produces less mitochondrial toxicity than the NRTIs. Nausea, vomiting, flatulence, and diarrhea occur in 10% or fewer patients. Resistance to tenofovir has been documented, and cross-resistance to NRTIs may occur.

Tenofovir Preparation Products And Raw materials

Raw materials

Preparation Products

Tenofovir Suppliers

Global( 425)Suppliers
Supplier Tel Fax Email Country ProdList Advantage
Shanghai Yingrui Biopharma Co., Ltd.
+86-21-34979012 CHINA 739 60
Shanghai Yingrui Biopharma Co.,Ltd
+86-21-34979012 CHINA 1321 58
Capot Chemical Co.,Ltd.
+86-571-85864795 China 19929 60
Henan DaKen Chemical CO.,LTD.
+86-371-55531817 CHINA 21821 58
Nanjing Gold Pharmaceutical Technology Co. Ltd.
025-84209270 15906146951
025-84209270 CHINA 115 55
Beijing Cooperate Pharmaceutical Co.,Ltd.
+86-10-60279497 +86(0)15646567669
+86-10-60279497 CHINA 1817 55
Henan Tianfu Chemical Co.,Ltd.
0371-55170693 CHINA 22626 55
+86 21 5161 9050/ 5187 7795
+86 21 5161 9052/ 5187 7796 CHINA 24723 60
Anqing Chico Pharmaceutical Co., Ltd.
15380796838 CHINA 341 58
Hebei Chisure Biotechnology Co., Ltd.
0311 66567340 CHINA 1009 58

View Lastest Price from Tenofovir manufacturers

Image Release date Product Price Min. Order Purity Supply Ability Manufacturer
2020-04-30 Tenofovir
US $0.01-1.00 / KG 1KG 99% 50 tons Shaanxi Dideu Medichem Co. Ltd
2018-07-26 Tenofovir
US $100.00 / KG 1KG 99% Customized career henan chemical co
2018-07-25 Tenofovir
US $200.00 / KG 100G 98% 10KG,20KG career henan chemical co

147127-20-6(Tenofovir)Related Search:

Copyright 2017 © ChemicalBook. All rights reserved